iTeos Therapeutics (NASDAQ:ITOS) Earns “Equal Weight” Rating from Wells Fargo & Company
Wells Fargo & Company reaffirmed their equal weight rating on shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) in a research note published on Wednesday morning, MarketBeat.com reports. They currently have a $12.00 price target on the stock, down from their previous price target of $13.00. ITOS has been the topic of a number of […]
Wells Fargo & Company reaffirmed their equal weight rating on shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) in a research note published on Wednesday morning, MarketBeat.com reports. They currently have a $12.00 price target on the stock, down from their previous price target of $13.00. ITOS has been the topic of a number of […]
